<DOC>
	<DOCNO>NCT01984775</DOCNO>
	<brief_summary>This study conduct assess potential topically-applied GSK2894512 cream 3 concentration ( 0.5 % , 1 % , 2 % ) induce skin irritation site application healthy subject . Results study consider select concentration ( ) GSK2894512 evaluate Phase II Phase III clinical safety efficacy study . Approximately 40 subject enrol order least 30 evaluable subject complete study . The total duration subject participation may 50 day .</brief_summary>
	<brief_title>A Study Evaluate Irritation Potential GSK2894512 Cream Skin Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Petrolatum</mesh_term>
	<criteria>Aged 18 65 year , inclusive , time consent . In generally good overall health healthy skin potential test sit back . Skin tone potential test sit back erythema dermal reaction easily visualize , i.e. , Fitzpatrick skin type I ( always burn ; never tan ) , II ( usually burn ; tan difficulty ) , III ( sometimes mild burn ; gradually tan ) , IV ( rarely burn ; tan ease ) . Determination skin type base sunburn tan history response first 30 45 minute sun exposure . A woman eligible participate nonchildbearing potential , defined woman function ovary document bilateral tubal ligation/sterilization hysterectomy , bilateral oopherectomy , postmenopausal least 12 month spontaneous amenorrhea . History know suspect intolerance GSK2894512 , ingredient study product , adhesive tape/plaster , test chamber . Inability evaluate skin around potential test sit back due sunburn , unevenness skin tone , tattoo , scar , excessive hair , freckle , birthmark , mole , skin damage abnormality . Clinicallyrelevant skin disease , include psoriasis , eczema , atopic dermatitis , acne , dysplastic nevus , skin pathology , history skin cancer , may , opinion investigator , contraindicate participation interfere test site evaluation . Considered immunocompromised , clinicallyrelevant history currently suffer disease condition , opinion investigator , might affect evaluation study product place subject undue risk . Used prohibit concomitant medication product within define washout period Day 1 visit . This include investigational product , allergy injection , immunization , corticosteroid , immunomodulators , antiinflammatories , antihistamine , selective leukotriene receptor antagonist , mast cell stabilizer , topical medication product around potential test site . Participation interventional clinical study within 4 week Day 1 Visit . A clinically relevant history current evidence abuse alcohol drug . Considered vulnerable ( e.g. , individual detention/institutionalized due legal regulatory order ) . Employee study center , bioskin GmbH , Parexel , GlaxoSmithKline ( GSK ) , Stiefel involve study , immediate family member ( e.g. , partner , offspring , parent , sibling , sibling 's offspring ) employee involve study . Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . Alanine aminotransferase ( ALT ) , alkaline phosphatase , bilirubin &gt; 1.5x upper limit normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . QTc &gt; =450 millisecond ( msec ) QTc &gt; =480 msec subject bundle branch block . The QTc QT interval correct heart rate accord Fridericia 's formula ( QTcF ) , machine overread . The QTc base single average QTc value triplicate ECGs obtain brief recording period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>safety</keyword>
	<keyword>dermal</keyword>
	<keyword>GSK2894512</keyword>
	<keyword>Cumulative irritation</keyword>
</DOC>